BRPI0414592A - antagonistas de receptores de trombina - Google Patents
antagonistas de receptores de trombinaInfo
- Publication number
- BRPI0414592A BRPI0414592A BRPI0414592-5A BRPI0414592A BRPI0414592A BR PI0414592 A BRPI0414592 A BR PI0414592A BR PI0414592 A BRPI0414592 A BR PI0414592A BR PI0414592 A BRPI0414592 A BR PI0414592A
- Authority
- BR
- Brazil
- Prior art keywords
- receptor antagonists
- thrombin receptor
- thrombin
- trombine
- series
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
"ANTAGONISTAS DE RECEPTORES DE TROMBINA". A invenção refere-se a uma série de compostos representados pelas fórmulas estruturais
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/671,216 US7488742B2 (en) | 2000-06-15 | 2003-09-25 | Thrombin receptor antagonists |
PCT/US2004/031495 WO2005030712A2 (en) | 2003-09-25 | 2004-09-23 | Thrombin receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0414592A true BRPI0414592A (pt) | 2006-11-07 |
Family
ID=34393462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0414592-5A BRPI0414592A (pt) | 2003-09-25 | 2004-09-23 | antagonistas de receptores de trombina |
Country Status (21)
Country | Link |
---|---|
US (3) | US7488742B2 (pt) |
EP (1) | EP1663965B1 (pt) |
JP (1) | JP4694490B2 (pt) |
KR (1) | KR20060128848A (pt) |
CN (1) | CN101128457A (pt) |
AR (1) | AR045809A1 (pt) |
AU (1) | AU2004276327B2 (pt) |
BR (1) | BRPI0414592A (pt) |
CA (1) | CA2540163C (pt) |
CO (1) | CO5680428A2 (pt) |
EC (1) | ECSP066455A (pt) |
IL (1) | IL174538A0 (pt) |
MX (1) | MXPA06003379A (pt) |
MY (1) | MY143834A (pt) |
NO (1) | NO20061797L (pt) |
PE (1) | PE20050471A1 (pt) |
RU (1) | RU2367660C9 (pt) |
SG (1) | SG147466A1 (pt) |
TW (1) | TWI331608B (pt) |
WO (1) | WO2005030712A2 (pt) |
ZA (1) | ZA200602448B (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
DE60331114D1 (de) * | 2002-04-16 | 2010-03-11 | Schering Corp | Trizyklische Thrombinrezeptorantagonisten |
JP4671123B2 (ja) * | 2003-06-23 | 2011-04-13 | 小野薬品工業株式会社 | 新規三環性複素環化合物 |
JP4558788B2 (ja) * | 2004-05-28 | 2010-10-06 | シェーリング コーポレイション | トロンビンレセプターアンタゴニストとしての条件付きヒンバシンアナログ |
US20060063930A1 (en) * | 2004-08-20 | 2006-03-23 | Agoston Gregory E | Compositions and methods comprising proteinase activated receptor antagonists |
AU2005294265A1 (en) * | 2004-10-06 | 2006-04-20 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
MX2007004197A (es) * | 2004-10-08 | 2007-06-15 | Schering Corp | Antagonistas del receptor de trombina. |
US7964726B2 (en) * | 2004-12-22 | 2011-06-21 | Ono Pharmaceutical Co., Ltd. | Tricyclic compound and use thereof |
PT1848705E (pt) * | 2005-01-14 | 2010-05-10 | Schering Corp | Sínteses exo- e diastereo-selectivas de análogos da himbacina |
EP1863778B1 (en) * | 2005-03-31 | 2015-12-30 | Merck Sharp & Dohme Corp. | Spirocyclic thrombin receptor antagonists |
US20070219154A1 (en) * | 2005-12-20 | 2007-09-20 | Suxing Liu | Methods for preventing and/or treating a cell proliferative disorder |
EP1971336A2 (en) * | 2005-12-22 | 2008-09-24 | Shering Corporation | Thrombin receptor antagonists as phophylaxis to complications from cardiopulmonary surgery |
CA2634907A1 (en) * | 2005-12-22 | 2007-07-05 | Schering Corporation | Oxazoloisoquinoline derivatives as thrombin receptor antagonists |
CA2647933A1 (en) * | 2006-03-29 | 2007-11-08 | Schering Corporation | Monocyclic and bicyclic himbacine derivatives useful as thrombin receptor antagonists |
AR060354A1 (es) * | 2006-04-06 | 2008-06-11 | Schering Corp | Terapias de combinacion antagonistas receptor trombina (tra) |
EP2266976B1 (en) * | 2006-04-13 | 2013-07-31 | Merck Sharp & Dohme Corp. | Fused ring thrombin receptor antagonists |
AU2007269830A1 (en) | 2006-06-29 | 2008-01-10 | Schering Corporation | Substituted bicyclic and tricyclic thrombin receptor antagonists |
TWI367112B (en) * | 2006-06-30 | 2012-07-01 | Schering Corp | Immediate-release tablet formulations of a thrombin receptor antagonist |
DE102006036023A1 (de) * | 2006-08-02 | 2008-02-07 | Sanofi-Aventis | Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität |
TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
EP2069326B1 (en) * | 2006-10-04 | 2015-03-18 | Merck Sharp & Dohme Corp. | Bicyclic and tricyclic derivatives as thrombin receptor antagonists |
MX2009006873A (es) * | 2006-12-22 | 2009-07-03 | Schering Corp | Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida. |
WO2008118320A1 (en) * | 2007-03-23 | 2008-10-02 | Schering Corporation | Reduction of adverse events.after percutaneous intervention by use of a thrombin receptor antagonist |
JP2011511018A (ja) | 2008-02-05 | 2011-04-07 | サノフィ−アベンティス | Par1阻害剤としてのsf5誘導体、その製造、及び薬剤としての使用 |
KR20100114514A (ko) | 2008-02-05 | 2010-10-25 | 사노피-아벤티스 | Par1 억제제로서의 트리아졸로피리다진, 이의 제조방법 및 약제로서의 용도 |
KR20100120139A (ko) * | 2008-02-05 | 2010-11-12 | 사노피-아벤티스 | Par1 억제제로서의 트리아졸륨 염, 이들의 제조방법, 및 약제로서의 용도 |
SI2438060T1 (sl) | 2009-06-04 | 2014-04-30 | Merck Sharp & Dohme Corp. | Aktivni metabolit trombin receptorskega antagonista |
EP2440191A2 (en) | 2009-06-08 | 2012-04-18 | Schering Corporation | A thrombin receptor antagonist and clopidogrel fixed dose tablet |
PL2558465T3 (pl) | 2010-04-16 | 2015-05-29 | Sanofi Sa | Trycykliczne pirydylo-winylo-pirole jako inhibitory receptora aktywowanego proteazą 1 (PAR1) |
PL2558462T3 (pl) | 2010-04-16 | 2015-03-31 | Sanofi Sa | Pirydylo-winylo-pirazolo-chinoliny jako inhibitory PAR1 |
US9340530B2 (en) | 2012-03-06 | 2016-05-17 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists |
WO2015013083A1 (en) | 2013-07-22 | 2015-01-29 | Merck Sharp & Dohme Corp. | Co-crystal of the par-1 receptor antagonist vorapaxar and aspirin |
US9701669B2 (en) | 2013-08-22 | 2017-07-11 | Merck Sharp & Dohme Corp. | Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists |
EP3035930A4 (en) | 2013-08-22 | 2017-03-08 | Merck Sharp & Dohme Corp. | 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives |
US9808473B2 (en) | 2013-08-22 | 2017-11-07 | Merck Sharp & Dohme Corp. | Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists |
JPWO2016114386A1 (ja) * | 2015-01-15 | 2017-10-19 | 国立研究開発法人国立精神・神経医療研究センター | 進行型免疫性脱髄疾患治療剤 |
CN110407819B (zh) * | 2019-08-02 | 2020-06-26 | 牡丹江医学院 | 一种作为预防外科手术并发症的凝血酶受体拮抗剂 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000229961A (ja) * | 1998-12-11 | 2000-08-22 | Sagami Chem Res Center | ヒドロナフト[2,3−c]フラン誘導体およびその製造方法 |
US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
SK287026B6 (sk) * | 2000-06-15 | 2009-10-07 | Schering Corporation | Nor-seko-himbacínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
JP4307260B2 (ja) * | 2001-10-18 | 2009-08-05 | シェーリング コーポレイション | トロンビンレセプタアンタゴニストとしてのヒンバシン類似物 |
DE60331114D1 (de) * | 2002-04-16 | 2010-03-11 | Schering Corp | Trizyklische Thrombinrezeptorantagonisten |
JP4558788B2 (ja) * | 2004-05-28 | 2010-10-06 | シェーリング コーポレイション | トロンビンレセプターアンタゴニストとしての条件付きヒンバシンアナログ |
PT1848705E (pt) * | 2005-01-14 | 2010-05-10 | Schering Corp | Sínteses exo- e diastereo-selectivas de análogos da himbacina |
SG158884A1 (en) * | 2005-01-14 | 2010-02-26 | Schering Corp | An exo-selective synthesis of himbacine analogs |
US20060172397A1 (en) * | 2005-01-14 | 2006-08-03 | Schering Corporation | Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs |
US7541471B2 (en) * | 2005-01-14 | 2009-06-02 | Schering Corporation | Synthesis of himbacine analogs |
-
2003
- 2003-09-25 US US10/671,216 patent/US7488742B2/en not_active Expired - Lifetime
-
2004
- 2004-09-23 CA CA2540163A patent/CA2540163C/en not_active Expired - Fee Related
- 2004-09-23 MX MXPA06003379A patent/MXPA06003379A/es active IP Right Grant
- 2004-09-23 EP EP04789042.1A patent/EP1663965B1/en active Active
- 2004-09-23 KR KR1020067005753A patent/KR20060128848A/ko not_active Application Discontinuation
- 2004-09-23 AU AU2004276327A patent/AU2004276327B2/en not_active Ceased
- 2004-09-23 WO PCT/US2004/031495 patent/WO2005030712A2/en active Application Filing
- 2004-09-23 AR ARP040103439A patent/AR045809A1/es unknown
- 2004-09-23 RU RU2006113638/04A patent/RU2367660C9/ru not_active IP Right Cessation
- 2004-09-23 SG SG200807889-1A patent/SG147466A1/en unknown
- 2004-09-23 TW TW093128874A patent/TWI331608B/zh not_active IP Right Cessation
- 2004-09-23 BR BRPI0414592-5A patent/BRPI0414592A/pt not_active IP Right Cessation
- 2004-09-23 PE PE2004000927A patent/PE20050471A1/es not_active Application Discontinuation
- 2004-09-23 CN CNA2004800278261A patent/CN101128457A/zh active Pending
- 2004-09-23 JP JP2006528258A patent/JP4694490B2/ja not_active Expired - Fee Related
- 2004-09-24 MY MYPI20043931A patent/MY143834A/en unknown
-
2006
- 2006-03-23 IL IL174538A patent/IL174538A0/en unknown
- 2006-03-23 CO CO06029040A patent/CO5680428A2/es not_active Application Discontinuation
- 2006-03-24 ZA ZA200602448A patent/ZA200602448B/en unknown
- 2006-03-24 EC EC2006006455A patent/ECSP066455A/es unknown
- 2006-04-24 NO NO20061797A patent/NO20061797L/no not_active Application Discontinuation
-
2008
- 2008-10-30 US US12/261,514 patent/US20090076088A1/en not_active Abandoned
- 2008-10-30 US US12/261,545 patent/US20090069383A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2367660C2 (ru) | 2009-09-20 |
MXPA06003379A (es) | 2006-06-08 |
AR045809A1 (es) | 2005-11-16 |
KR20060128848A (ko) | 2006-12-14 |
TWI331608B (en) | 2010-10-11 |
US7488742B2 (en) | 2009-02-10 |
JP4694490B2 (ja) | 2011-06-08 |
CA2540163A1 (en) | 2005-04-07 |
WO2005030712A2 (en) | 2005-04-07 |
CA2540163C (en) | 2012-06-05 |
WO2005030712A3 (en) | 2007-09-20 |
RU2006113638A (ru) | 2007-11-10 |
WO2005030712A8 (en) | 2007-12-21 |
IL174538A0 (en) | 2006-08-01 |
CN101128457A (zh) | 2008-02-20 |
US20040152736A1 (en) | 2004-08-05 |
AU2004276327A1 (en) | 2005-04-07 |
NO20061797L (no) | 2006-05-19 |
EP1663965A2 (en) | 2006-06-07 |
ECSP066455A (es) | 2006-09-18 |
TW200524914A (en) | 2005-08-01 |
SG147466A1 (en) | 2008-11-28 |
CO5680428A2 (es) | 2006-09-29 |
MY143834A (en) | 2011-07-15 |
US20090069383A1 (en) | 2009-03-12 |
US20090076088A1 (en) | 2009-03-19 |
RU2367660C9 (ru) | 2010-08-10 |
EP1663965B1 (en) | 2014-04-09 |
ZA200602448B (en) | 2007-09-26 |
PE20050471A1 (es) | 2005-08-24 |
JP2007523051A (ja) | 2007-08-16 |
AU2004276327B2 (en) | 2010-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0414592A (pt) | antagonistas de receptores de trombina | |
CR8475A (es) | Fenilalanina-amidas sustituidas por benzoilo | |
CY1112011T1 (el) | Παραγωγα αζαδικυκλο (3.1.0) εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης | |
ATE429427T1 (de) | Pyrimidinderivate als orexin-rezeptorantagonisten | |
UY28290A1 (es) | Compuestos farmacéuticos novedosos | |
EA200700365A1 (ru) | Производные индол-2-карбоксамидина как антагонисты nmda рецептора | |
ATE463495T1 (de) | Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten | |
NO20071642L (no) | N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger | |
DK1379239T3 (da) | N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren | |
TW200745056A (en) | Diaminopyrimidines as P2X3 and P2X2/3 modulators | |
TW200613256A (en) | Photoactive compounds | |
CY1105994T1 (el) | Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων | |
ATE340795T1 (de) | Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten | |
NO20060195L (no) | Kinolylamidderivater som CCR-5-antagonister | |
CY1108880T1 (el) | Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα | |
EA200600197A1 (ru) | Получение производных соединения 1,3-дифенилпроп-2-ен-1-он | |
TNSN06012A1 (en) | Emulsifying systems containing azetidine derivatives | |
NO20063293L (no) | Farmasoytiske forbindelser | |
MA32834B1 (fr) | 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines | |
CY1107101T1 (el) | Μεθοδος συνθεσης παραγωγων της 1,3-διϋδρο-2h-3-βενζαζεπιν-2-ονης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης με φαρμακευτικως αποδεκτο οξυ | |
BRPI0417950A (pt) | composições farmacêuticas | |
BR0307156A (pt) | Derivado de pirimidina bicìclica fundida, composto, antagonistas de receptores e agentes profiláticos e terapêuticos | |
ATE447575T1 (de) | Selektive spirocyclische glucocorticoid-rezeptor- modulatoren | |
ATE282041T1 (de) | Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist | |
NO20060603L (no) | Fremgangsmate for fremstillingen av fenyltetrazolderivater |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2168 DE 24/07/2012. |